TCM
BIO icon

Thames Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Thames Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,146
Closed -$8.69M – 25
2023
Q1 		$8.69M Buy
+18,146
New +$8.49M 6.12% 6
2018
Q1 		– Sell
-32,010
Closed -$7.64M – 31
2017
Q4 		$7.64M Buy
+32,010
New +$7.76M 4.8% 5

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Thames Capital Management's BIO Position: Q2 2023 in Review

Thames Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 18,146 shares — an estimated $8.69M sold.

Thames Capital Management first reported a position in BIO in Q4 2017 and held it in 2 quarters. The position peaked at $8.69M in Q1 2023. 468 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • Thames Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • Thames Capital Management sold 18,146 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $8.69M.
  • Thames Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and held it in 2 quarters.
  • Thames Capital Management's Bio-Rad Laboratories Class A position peaked at $8.69M in Q1 2023.
  • 468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Thames Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.